Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for BridgeBio Pharma Inc. (BBIO:NASDAQ), powered by AI.
BridgeBio Pharma Inc. is currently trading at $66.80. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for BridgeBio Pharma Inc. on Alpha Lenz.
BridgeBio Pharma Inc.'s P/E ratio is -17.6.
“BridgeBio Pharma Inc. trades at a P/E of -17.6 (undervalued) with strong ROE of 40.8%. 3Y revenue CAGR of 86.3% highlights clear growth momentum.”
Ask for details →BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.
“BridgeBio Pharma Inc. trades at a P/E of -17.6 (undervalued) with strong ROE of 40.8%. 3Y revenue CAGR of 86.3% highlights clear growth momentum.”
Ask for details →BridgeBio Pharma Inc. (ticker: BBIO) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 725 employees. Market cap is $12.8B.
The current price is $66.8 with a P/E ratio of -17.65x and P/B of -6.13x.
ROE is 40.79% and operating margin is -100.00%. Annual revenue is $502M.